PARSIPPANY, NJ--(Marketwire - January 06, 2009) - The Medicines Company (NASDAQ: MDCO) is scheduled to participate in the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13th, at 9am Pacific Time, 12:00pm Eastern Time. A company overview and outlook will be provided in the presentation.
The session will be webcast with a link available at The Medicines Company’s website: http://www.themedicinescompany.com.
MDCO-G
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has an investigational antiplatelet agent, cangrelor, in late-stage development and a serine protease inhibitor, CU-2010, in early-stage development. The Company’s website is www.themedicinescompany.com.
Contact:
Robyn Brown
Vice President, Investor Relations
The Medicines Company
973-656-1616
Email Contact
